Similar Items: IGF2BP3 inhibition: another home run for RNA-binding protein targeting in hematological malignancies
- A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity
- Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings
- Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Experience of 15 Years in Polish Pediatric Hematology Centers
- Prevalence, Risk Factors, and Prognostic Impact of Spontaneous Tumor Lysis Syndrome in Aggressive Hematologic Malignancies: Experience From the Clinical Hematology Department, University of Dakar
- A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns
- Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review